drugset / Trial / NCT05736978
Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, single-arm, multi-center clinical trial to evaluate the efficacy and safety of selinexor in combination with azacitidine and venetoclax for untreated acute myeloid leukemia based on MRD results on day 14 of the first cycle.
Timeline
- Start
- 2023-03-31
- Primary completion
- 2025-03-01
- Completion
- 2027-03-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 75 mg/m2 | — |
| Subject | Selinexor | Other / unclassified | 60 mg | — |
| Subject | Venetoclax | Small molecule | 400 mg | — |